APO-AMITRIPTYLINE

Main information

  • Trade name:
  • APO-AMITRIPTYLINE 25 amitriptyline hydrochloride 25mg tablet bottle pack
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • APO-AMITRIPTYLINE 25 amitriptyline hydrochloride 25mg tablet bottle pack
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 215363
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

215363

APO-AMITRIPTYLINE 25 amitriptyline hydrochloride 25mg tablet bottle pack

ARTG entry for

Medicine Registered

Sponsor

Apotex Pty Ltd

Postal Address

PO Box 280,NORTH RYDE BC, NSW, 1670

Australia

ARTG Start Date

22/08/2014

Product category

Medicine

Status

Active

Approval area

Drug Safety Evaluation Branch

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. APO-AMITRIPTYLINE 25 amitriptyline hydrochloride 25mg tablet bottle pack

Product Type

Single Medicine Product

Effective date

26/05/2016

Warnings

See Product Information and Consumer Medicine Information for this product

Standard Indications

Specific Indications

For the treatment of major depression. Amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,Nocturnal

enuresis where organic pathology has been excluded.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Bottle

HDPE

12 Months

Store below 25

degrees Celsius

Neither child resistant

closure nor restricted

flow insert

Not recorded

Pack Size/Poison information

Pack Size

Poison Schedule

(S4) Prescription Only Medicine

Components

1. APO-AMITRIPTYLINE 25 amitriptyline hydrochloride 25mg tablet bottle pack

Dosage Form

Tablet

Route of Administration

Oral

Visual Identification

Yellow colour, circular, biconvex, film coated tablets with 'IA' over '25'

debossed on one side and plain on the other side

Active Ingredients

amitriptyline hydrochloride

25 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 26.11.2017 at 08:56:49 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Summary of Product characteristics: dosage,interactions,side effects

Product Information – Australia

APO-Amitriptyline Tablets

Page 1

APO-Amitriptyline 10 Tablets

APO-Amitriptyline 25 Tablets

APO-Amitriptyline 50 Tablets

NAME OF THE MEDICINE

Amitriptyline hydrochloride

Active Ingredient

Chemical Name:

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-

dimethylpropylamine hydrochloride

Structural Formula:

Molecular Formula:

N.HCl

Molecular Weight:

313.9

CAS Registry Number:

549-18-8

DESCRIPTION

Amitriptyline hydrochloride occurs as colourless crystals or a white or almost white powder; odourless

or almost odourless; taste, bitter and burning, followed by a sensation of numbness. It is soluble in 1

part of water, in 1.5 parts of ethanol (96%), in 1.2 parts of chloroform and in 1 part of methanol. It is

practically insoluble in ether. pKa of amitriptyline hydrochloride is 9.4.

Each tablet contains amitriptyline hydrochloride as the active ingredient. In addition, each tablet

contains the following inactive ingredients: lactose, microcrystalline cellulose, crospovidone, maize

starch, colloidalanhydrous silica, purified talc, magnesium stearate, hypromellose, titanium dioxide,

macrogol 6000, brilliant blue FCF aluminium lake (10mg only), quinoline yellow aluminium lake (25mg

only), sunset yellow FCF aluminium lake and indigo carmine aluminium lake (50mg only).

PHARMACOLOGY

Amitriptyline is a tricyclic antidepressant with sedative properties.

Mechanism of action

The mechanism of action of amitriptyline in man is not known. It is not a monoamine oxidase inhibitor

and it does not act primarily by stimulation of the central nervous system. In broad clinical use,

amitriptyline has been found to be well tolerated.

Amitriptyline inhibits the membrane pump mechanism responsible for uptake of noradrenaline and

serotonin in adrenergic and serotonergic neurons. Pharmacologically, this action may potentiate or

prolong neuronal activity since reuptake of these biogenic amines is important physiologically in

terminating its transmitting activity. This interference with the uptake of noradrenaline and/or serotonin

is believed by some to underlie the antidepressant activity of amitriptyline.

Amitriptyline has also been found to be effective in the treatment of enuresis in some cases where

organic pathology has been excluded. The mode of action of amitriptyline in enuresis is not known.

Product Information – Australia

APO-Amitriptyline Tablets

Page 2

However, amitriptyline does have anticholinergic properties and medicines of this group, such as

belladonna, have been used in the treatment of enuresis.

Pharmacokinetics

Amitriptyline is readily absorbed from the gastrointestinal tract, with peak plasma concentrations

occurring within approximately 6 hours of oral administration.

The mean apparent elimination half-life for amitriptyline was reported by one source to be 22.4 hours;

the mean half- life of its active metabolite, nortriptyline was 26 hours.

Amitriptyline is approximately 96% bound to plasma proteins.

Amitriptyline undergoes extensive metabolism in the liver, primarily through N-demethylation, to

nortriptyline. Paths of metabolism of both amitriptyline and nortriptyline include hydroxylation and N-

oxidation.

Amitriptyline is excreted in the urine, mainly in the form of metabolites, either free or as glucuronide

and sulphate conjugates. Very little unchanged medicine is excreted in the urine. From one-third to

one-half of an oral radioactive dose is excreted in the urine within 24 hours of administration.

INDICATIONS

treatment

of major

depression.

Amitriptyline

tablets

indicated

only

maintenance treatment of major depression (see Precautions).

Nocturnal enuresis where organic pathology has been excluded.

CONTRAINDICATIONS

Amitriptyline is contraindicated in patients who have shown prior hypersensitivity to it.

Monoamine Oxidase Inhibitors (MAOIs)

Amitriptyline should not be given concurrently with monoamine oxidase inhibitors, including selegiline.

The combination of amitriptyline with a monoamine oxidase inhibitor has caused severe convulsions,

hyperpyretic crises and death.

When it is desired to substitute amitriptyline for a monoamine oxidase inhibitor, a minimum of 14 days

should be allowed to elapse after the latter is discontinued. Amitriptyline should then be initiated

cautiously with gradual increase in dosage until optimum response is achieved.

Cisapride

Amitriptyline is contraindicated in patients taking cisapride due to the possibility of adverse cardiac

interactions including prolongation of the QT interval, cardiac arrhythmias and conduction system

disturbances.

Myocardial Infarction

Amitriptyline is not recommended for use during the acute recovery phase following myocardial

infarction.

See Precautions, Use in Pregnancy and Use in Lactation.

Product Information – Australia

APO-Amitriptyline Tablets

Page 3

PRECAUTIONS

Clinical Worsening and Suicide Risk associated with Psychiatric Disorders

The risk of suicide attempt is inherent in depression and may persist until significant remission occurs.

This risk must be considered in all depressed patients.

Patients with depression, both adult and paediatric, may experience worsening of their depressive

symptoms and/or the emergence of suicidal ideation and behaviour (suicidality), whether or not they

are taking antidepressant medications, and this risk may persist until significant remission occurs. As

improvement may not occur during the first few weeks or more of treatment, patients should be closely

monitored for clinical worsening and suicidality, especially at the beginning of a course of treatment, or

at the time of dose changes, either increases or decreases. Consideration should be given to

changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose

depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not

part of the patient‟s presenting symptoms.

Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of

their condition and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves

seek

medical

advice

immediately

these

symptoms

present.

Patients

with

co-morbid

depression associated with other psychiatric disorders being treated with antidepressants should be

similarly observed for clinical worsening and suicidality.

Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others)

showed that these drugs increase the risk of suicidal thinking and behaviour (suicidality) in children,

adolescents and young adults (ages 18-24) with major depressive disorder and other psychiatric

disorders. Short term-studies did not show an increase in risk of suicidality with antidepressants

compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared

to placebo in adults aged 65 and older.

Pooled analyses of 24 short-term (4 to 16 weeks), placebo-controlled trials of nine antidepressant

medicines (SSRIs and others) in 4400 children and adolescents with major depressive disorder (16

trials), obsessive compulsive disorder (4 trials), or other psychiatric disorders (4 trials) have revealed a

greater risk of adverse events representing suicidal behaviour or thinking (suicidality) during the first

few months of treatment in those receiving antidepressants. The average risk of such events in

patients treated with an antidepressant was 4%, compared with 2% of patients given placebo. There

was considerable variation in risk among the antidepressants, but there was a tendency towards an

increase for almost all antidepressants studied. The risk of suicidality was most consistently observed

in the major depressive disorder trials, but there were signals of risk arising from trials in other

psychiatric indications (obsessive compulsive disorder and social anxiety disorder) as well. No

suicides occurred in these trials. It is unknown whether the suicidality risk in children and adolescent

patients extends to use beyond several months. The nine antidepressant medicines in the pooled

analyses included five SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) and four non-

SSRIs (bupropion, mirtazapine, nefazodone, venlafaxine).

The pooled analyses of placebo-controlled trials in adults with major depressive disorder or other

psychiatric disorders included a total of 295 short-term trials (average duration of 2 months) of 11

antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality

among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.

Absolute risk of suicidality varied across the different indications, with the highest incidence in major

depressive disorder. The risk differences (drug vs. placebo), however, were relatively stable within age

strata and across indications. These risk differences (drug-placebo difference in the number of cases

of suicidality per 1000 patients treated) are provided in Table 1.

Product Information – Australia

APO-Amitriptyline Tablets

Page 4

Table 1

Age Range

Drug-Placebo Difference in Number of Cases of

Suicidality per 1000 Patients Treated

Drug-Related Increases

<18

14 additional cases

18-24

5 additional cases

Drug-Related Decreases

25-64

1 fewer case

65

6 fewer cases

There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about

drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e. beyond several months.

However, there is substantial evidence from placebo-controlled maintenance trials in adults with

depression that the use of antidepressants can delay the recurrence of depression.

Symptoms

anxiety,

agitation,

panic

attacks,

insomnia,

irritability,

hostility

(aggressiveness),

impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in

adults, adolescents and children being treated with antidepressants for major depressive disorder as

well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the

emergence of such symptoms and either worsening of depression and/or emergence of suicidal

impulses has not been established, there is concern that such symptoms may be precursors of

emerging suicidality.

Families and caregivers of children, adolescents and young adults (ages 18-24) being treated with

antidepressants

major

depressive

disorder

other

condition

(psychiatric

non-

psychiatric) should be informed about the need to monitor these patients for the emergence of

agitation, irritability, unusual changes in behaviour, and other symptoms described above, as well as

the emergence of suicidality, and to report such symptoms immediately to health care providers. It is

particularly important that monitoring be undertaken during the initial few months of antidepressant

treatment or at times of dose increase or decrease.

Prescriptions for amitriptyline should be written for the smallest quantity of tablets consistent with good

patient

management, in order to reduce the risk of overdose.

Amitriptyline 50 mg Tablets

The 50 mg tablets are indicated only for the maintenance treatment of major depression. The 50 mg

tablets should not be used in acutely ill patients where there is a risk of suicide. There is an increased

risk of completed suicide by overdose with the 50 mg tablet compared with the 25 mg tablet.

To prevent accidental overdose and the potentially fatal consequences, patients should be made

aware of the unusual toxicity of tricyclic antidepressants and the need to maintain strict control over

the tablets as well as the need to store them out of reach of children.

Bipolar Disorder and Activation of Mania/Hypomania

A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed

that treating such an episode with an antidepressant alone can increase the likelihood of precipitation

of a mixed/manic episode in patients at risk of bipolar disorder. Prior to initiating treatment with an

antidepressant, patients should be adequately screened to determine if they are at risk for bipolar

disorder; such screening should include detailed psychiatric history, including a family history of

suicide, bipolar disorder and depression.

Seizures

Amitriptyline should be used with caution in patients with a history of seizures.

Central Nervous Disorders

The possibility of suicide in depressed patients remains during treatment. Patients should not have

access to large quantities of this medicine during treatment.

Product Information – Australia

APO-Amitriptyline Tablets

Page 5

When

amitriptyline

hydrochloride

used

treat

depressive

component

schizophrenia,

psychotic symptoms may be aggravated. Likewise, in manic depressive psychosis, depressed patients

may experience a shift toward the manic phase. Paranoid delusions, with or without associated

hostility, may be exaggerated. In any of these circumstances, it may be advisable to reduce the dose

of amitriptyline or to use a major tranquillising medicine, such as perphenazine, concurrently.

Glaucoma and Urinary Retention

Due to its atropine-like action, amitriptyline should be used with caution in patients with a history of

urinary retention, or with narrow angle glaucoma or increased intraocular pressure. In patients with

narrow angle glaucoma, even average doses precipitate an attack.

Cardiovascular Disorders

Patients with cardiovascular disorders should be watched closely. Tricyclic antidepressant medicines,

including amitriptyline hydrochloride, particularly when given in high doses, have been reported to

produce arrhythmias, sinus tachycardia, and prolongation of the conduction time. Myocardial infarction

and stroke have been reported with medicines of this class.

Endocrine Disorders

Close supervision is required when amitriptyline is given to hyperthyroid patients or those receiving

thyroid medication (see Interactions with other medicines).

Other Antidepressant Medicines

The addition of other antidepressant medicines generally does not result in any additional therapeutic

benefit. Untoward reactions have been reported after the combined use of antidepressant agents

having varying modes of activity. Therefore, combined use of amitriptyline hydrochloride and other

antidepressant medicines should

undertaken only

with

due recognition

of the possibility

potentiation and with a thorough knowledge of the pharmacology of both medicines. There has been

evidence

potentiation

when

patients

receiving

amitriptyline

hydrochloride

were

changed

immediately to protriptyline or vice versa.

Elective Surgery

Discontinue the medicine several days before elective surgery if possible.

Impairment of Motor Co-ordination

Amitriptyline may impair alertness in some patients; operation of motor vehicles and other activities

made hazardous by diminished alertness should be avoided.

Use in Hepatic Impairment

In the presence of hepatic disease, amitriptyline should be used cautiously.

Use in Pregnancy (Category C)

Withdrawal symptoms in newborn infants have been reported with prolonged maternal use of this

class of medicines.

Tricyclic antidepressants have not been shown to be associated with an increased incidence of birth

defects. However, there is evidence of interference with central monoamine neurotransmission in rats.

Care should be taken that there are sound indications for the use of these antidepressants in

pregnancy.

There are no well controlled studies in pregnant women; therefore, in administering amitriptyline to

pregnant women or women who may become pregnant, the potential benefits must be weighed

against the possible hazards to mother and child.

Use in Lactation

Amitriptyline is detectable in breast milk. Because of the potential for serious adverse effects in infants

from amitriptyline, a decision should be made whether to discontinue nursing or discontinue the

medicine.

Use in Children and Adolescents (<18 years)

Product Information – Australia

APO-Amitriptyline Tablets

Page 6

The safety and efficacy of amitriptyline for the treatment of depression or other psychiatric disorders in

children and adolescents aged less than 18 years has not been satisfactorily established. Amitriptyline

should not be used in this age group for the treatment of depression.

Carcinogenicity

Long-term carcinogenicity studies in rodents have not been performed with amitriptyline. Genotoxicity

studies have not been performed with amitriptyline. Accumulated data from up to 19 years follow-up in

approximately 2,00 patients showed no statistically significant association between treatment with

amitriptyline and the incidence of cancers. Clinical experience over 30 years has produced no

evidence of an altered carcinogenic risk.

Genotoxicity

Genotoxicity studies have not been performed with amitriptyline.

INTERACTIONS WITH OTHER MEDICINES

Other antidepressant medicines

A potentially lethal interaction can occur between monoamine oxidase inhibitors (MAOIs) and tricyclic

antidepressants. It is advisable to discontinue the MAOI for at least 2 weeks before taking amitriptyline

(see Contraindications).

Concurrent

fluoxetine

tricyclic

antidepressants

produced

increased

plasma

concentrations of the tricyclic antidepressants. Some clinicians recommend dosage reductions for

tricyclic antidepressants of about 50% if used concurrently with fluoxetine. Any patient receiving

amitriptyline

fluoxetine

concurrently

should

observed

closely

adverse

effects

consideration should be given to monitoring the plasma levels of the tricyclic antidepressant with

dosage reduction where necessary.

There have been no reports of untoward events when patients receiving amitriptyline hydrochloride

were changed immediately to protriptyline or vice versa.

Guanethidine

Amitriptyline may block the antihypertensive action of guanethidine or similarly acting compounds.

Anticholinergic agents/sympathomimetic medicines

When amitriptyline is given with anticholinergic agents or sympathomimetic medicines, including

adrenaline combined with local anaesthetics, close supervision and careful adjustment of dosage are

required. Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with

anticholinergic type medicines.

Anticholinergic agents/neuroleptic medicines

Hyperpyrexia has been reported when tricyclic antidepressants are administered with anticholinergic

agents

with

neuroleptic

medicines,

particularly

during

weather.

Concurrent

phenothiazines and tricyclic antidepressants have the potential to elevate plasma levels of both

agents. The sedative and anticholinergic effects may be prolonged and the risk of seizures and

neuroleptic malignant syndrome increased.

Medicines Metabolised By Cytochrome P450 2D6

Concomitant use of tricyclic antidepressants with medicines that can inhibit cytochrome P450 2D6

(e.g. quinidine; cimetidine) and those that are substrates for P450 2D6 (many other antidepressants,

phenothiazines, and the Type 1C antiarrhythmics, eg. flecainide) may require lower doses than usually

prescribed for either the tricyclic antidepressant or the other medicine. Whenever one of these other

medicines is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be

required. While all the selective serotonin reuptake inhibitors (SSRIs), e.g. fluoxetine, sertraline and

paroxetine, inhibit P 450 2D6, they may vary in the extent of inhibition.

Cimetidine

Product Information – Australia

APO-Amitriptyline Tablets

Page 7

Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby

delaying elimination and increasing steady state concentrations of these medicines.

Central nervous system depressants

Amitriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS

depressants

Disulfiram

Delirium has been reported with concurrent administration of amitriptyline and disulfiram.

Electroshock therapy

Concurrent administration of amitriptyline and electroshock therapy may increase the hazards of

therapy. Such treatment should be limited to patients for whom it is essential.

Antithyroid medicines

Concurrent use may increase the risk of agranulocytosis.

Thyroid hormones

Concurrent use with tricyclic antidepressants may increase the therapeutic and toxic effects of both

medications. Toxic effects include cardiac arrhythmias and CNS stimulation.

Analgesics

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.

Selective Serotonin Reuptake Inhibitors (SSRIs)

The "serotonin syndrome" (alterations in cognition, behaviour, autonomic nervous system function,

and neuromuscular activity) has been reported with amitriptyline when given concomitantly with other

serotonin-enhancing medicines including Selective Serotonin Reuptake Inhibitors (SSRIs).

Other medicines

Because tricyclic antidepressants may delay gastric emptying and decrease intestinal motility, careful

dosage monitoring is essential with any medicine that may be subject to gastric inactivation (ie.

levodopa) or which may be absorbed to a greater extent because of the increased time available for

absorption (ie. anticoagulants).

ADVERSE EFFECTS

Note. Included are a few adverse effects which have not been reported with this specific medicine.

However, pharmacological similarities among the tricyclic antidepressants require that each of the

effects be considered when amitriptyline is administered.

Cardiovascular

Hypotension, syncope, hypertension, tachycardia, palpitations, myocardial infarction, arrhythmias,

heart block, stroke, nonspecific ECG changes and changes in AV conduction.

Central nervous system and neuromuscular

Confusional

states,

disturbed

concentration,

disorientation,

delusions,

hallucinations,

excitement,

anxiety, restlessness, insomnia, drowsiness, nightmares; numbness, tingling, paraesthesiae of the

extremities, peripheral neuropathy, incoordination, ataxia, tremors, coma, seizures, alteration in EEG

patterns, extrapyramidal symptoms includingabnormal voluntary movements and tardive dyskinesia;

dysarthria, tinnitus. thrombocytopenia

Anticholinergic

mouth,

blurred

vision,

disturbance

accommodation,

constipation,

paralytic

ileus,

urinary

retention, dilatation of urinary tract, increased intraocular pressure, hyperpyrexia.

Allergic

Product Information – Australia

APO-Amitriptyline Tablets

Page 8

Skin rash, urticaria, pruritus, photosensitisation, oedema of face and tongue.

Haematological

Bone marrow depression including agranulocytosis, leucopenia, eosinophilia, purpura,

Gastrointestinal

Nausea, epigastric distress, vomiting, anorexia, stomatitis, peculiar taste, diarrhoea, parotid swelling,

black tongue, rarely hepatitis (including altered liver function and jaundice).

Endocrine

Testicular swelling and gynaecomastia in the male, breast enlargement and galactorrhoea in the

female, increased or decreased libido, impotence, elevation or

lowering of blood sugar levels,

syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Other

Dizziness, weakness, fatigue, headache, weight gain or loss, oedema, increased perspiration, urinary

frequency, mydriasis, drowsiness, alopecia.

Serotonin Syndrome

The “serotonin syndrome” (alterations in cognition, behaviour, autonomic nervous system function,

and neuromuscular activity) has been reported with amitriptyline when given concomitantly with other

serotonin-enhancing medicines.

Withdrawal symptoms

Abrupt cessation of treatment after prolonged administration may produce nausea, headache and

malaise. Gradual dosage reduction has been reported to produce, within two weeks, transient

symptoms

including

irritability,

restlessness,

dream

sleep

disturbance.

These

indicative of addiction. Rare instances have been reported of mania or hypomania occurring within 2 to

7 days following cessation of chronic therapy with tricyclic antidepressants.

In enuresis

The doses of amitriptyline recommended in the treatment of enuresis are low compared with those

used in the treatment of depression, even allowing for differences in age and weight. Consequently,

side effects are less frequent than when the medicine is used in treating depression. The most

common side effects are drowsiness and anticholinergic effects.

Causal relationship unknown

A lupus-like syndrome (migratory arthritis, positive ANA and rheumatoid factor) has been reported

rarely; however, a causal relationship to therapy with amitriptyline could not be established.

DOSAGE AND ADMINISTRATION

Depression

Dosage considerations.

Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response

and any evidence of intolerance.

Initial dosage for outpatient adults

.

75 mg a day in divided doses is usually satisfactory. If necessary, this may be increased to a total of

150 mg a day. Increases are made preferably in the late afternoon and/or bedtime doses. The

sedative effect is usually rapidly apparent. The antidepressant activity may be evident within three or

four days or may take up to 30 days to develop adequately.

Alternative methods for initiating therapy in outpatients are: begin therapy with 50 to 100 mg preferably

in the evening or at bedtime; this may be increased by 25 to 50 mg as necessary to a total of 150 mg

per day.

Product Information – Australia

APO-Amitriptyline Tablets

Page 9

Dosage for hospitalised patients

100 mg a day may be required initially. This can be increased gradually to 200 mg a day if necessary.

A small number of hospitalised patients may need as much as 300 mg per day.

Dosage for elderly patients.

In general, lower dosages are recommended for these patients. 50 mg daily may be satisfactory in

those

elderly

patients

tolerate

higher

doses.

required

daily

dose

administered either in divided doses or as a single dose preferably in the evening or at bedtime.

Maintenance dosage.

Usually from 50 to 100 mg per day. For maintenance therapy, the total daily dosage may be given in a

single dose preferably in the evening or at bedtime. When satisfactory improvement has been

reached, dosage should be reduced to the lowest amount that will maintain relief of symptoms. It is

appropriate to continue maintenance therapy 3 months or longer to lessen the possibility of relapse.

Enuresis

A dose of 10 mg at bedtime has been found effective in children under 6 years of age. In older

children, the dosage should be increased as necessary according to weight and age. Children 6 to 10

years of age may receive 10 to 20 mg per day. In the age group from 11 to 16, a dose of 25 to 50 mg

at bedtime may be required.

Most patients respond in the first few days of therapy. In those who do respond, the tendency is for

increasing, continued improvement as the period of treatment is extended. Continued treatment is

usually required to maintain the response until control is established.

The doses of amitriptyline recommended in the treatment of enuresis are low compared with those

used

treatment

depression,

even

allowing

differences

weight.

This

recommended dose must not be exceeded. This medication should be kept out of reach of children.

Plasma Levels

Because of the wide variation in the absorption and distribution of tricyclic antidepressants in body

fluids, it is difficult to directly correlate plasma levels and therapeutic effect. However, determination of

plasma levels may be useful in identifying patients who appear to have toxic effects and may have

excessively high levels, or those in whom lack of absorption or non-compliance is suspected.

Adjustments in dosage should be made according to the patient's clinical response and not on the

basis of plasma levels.

OVERDOSAGE

Deaths by deliberate or accidental overdosage have occurred with this class of medicine.

There has been a report of fatal dysrhythmia occurring as late as 56 hours after amitriptyline overdose.

Symptoms

High

doses

cause

temporary

confusion,

disturbed

concentration,

transient

visual

hallucinations. Overdosage may cause drowsiness, hypothermia, tachycardia and other arrhythmic

abnormalities, such as bundle branch block, ECG evidence of impaired conduction, congestive heart

failure, dilated pupils, convulsions, severe hypotension, stupor, coma and polyradiculoneuropathy.

Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators

of tricyclic antidepressant toxicity. Other symptoms may be agitation, hyperactive reflexes, muscle

rigidity, vomiting, hyperpyrexia, or any of those listed under Adverse Effects.

Treatment

All patients suspected of having taken an overdosage should be admitted to a hospital as soon as

possible. Treatment is symptomatic and supportive. Activated charcoal may reduce absorption of the

medicine if given within one or two hours after ingestion. In patients who are not fully conscious or

have impaired gag reflex, consideration should be given to administering activated charcoal via a

nasogastric tube, one the airway is protected. An ECG should be taken and close monitoring of

cardiac function instituted if there is any sign of abnormality. Maintain an open airway and adequate

fluid intake; regulate body temperature.

Product Information – Australia

APO-Amitriptyline Tablets

Page 10

Standard measures should be used to manage circulatory shock and metabolic acidosis. Cardiac

arrhythmias have been treated with propranolol. Should cardiac failure occur, the use of digitalis

should be considered. Close monitoring of cardiac function for not less than five days is advisable.

Anticonvulsants may be given to control convulsions. Amitriptyline increases the CNS depressant

action but not the anticonvulsant action of barbiturates; therefore, an inhalation anaesthetic or

diazepam is recommended for control of convulsions.

Dialysis is of no value because of low plasma concentrations of the medicine.

Since overdosage is often deliberate, patients may attempt suicide by other means during the

recovery phase.

In cases of overdosage, it is advisable to contact the Poisons Information Centre on 131126

(Australia) for recommendation on the management and treatment of overdosage.

PRESENTATION AND STORAGE CONDITIONS

APO-Amitriptyline tablets are intended for oral administration.

10mg tablet:

Blue colour, circular, biconvex, film coated tablets with “IA” over “10” debossed on one side and plain

on the other side.

Blister (PVC/Alu) pack of 20, 50 and 100 tablets (AUST R 215351).

Bottle (HDPE) pack of 100 tablets (AUST R 215370)

25mg tablet:

Yellow colour, circular, biconvex, film coated tablets with “IA” over “25” debossed on one side and

plain on the other side.

Blister (PVC/Alu) pack of 20, 50 and 100 tablets (AUST R 215380).

Bottle (HDPE) pack of 100 tablets (AUST R 215363)

50mg tablet:

Brown colour, circular, biconvex, film coated tablets with “IA” over “50” debossed on one side and

plain on the other side

Blister (PVC/Alu) pack of 20, 50 and 100 tablets (AUST R 215367).

Bottle (HDPE) pack of 100 tablets (AUST R 215390)

100 tablets pack size is for dispensing only. Not all strengths, pack types and/or pack sizes may be

available.

Storage

Store below 25ºC.

NAME AND ADDRESS OF THE SPONSOR

Apotex Pty Ltd

16 Giffnock Avenue

Macquarie Park NSW 2113

APO- and APOTEX- are registered trademarks of Apotex Inc.

POISON SCHEDULE OF THE MEDICINE

S4 – Prescription Only Medicine.

Date of first inclusion in the Australian Register of Therapeutic Goods (the ARTG): 22

August

2014

22-3-2019

Safety and efficacy of l‐lysine monohydrochloride and l‐lysine sulfate produced using Corynebacterium glutamicum CCTCC M 2015595 for all animal species

Safety and efficacy of l‐lysine monohydrochloride and l‐lysine sulfate produced using Corynebacterium glutamicum CCTCC M 2015595 for all animal species

Published on: Thu, 21 Mar 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on l‐lysine monohydrochloride and l‐lysine sulfate produced using Corynebacterium glutamicum CCTCC M 2015595 when used as nutritional additive in feed and water for drinking for all animal species. The active substance is l‐lysine and it is produced in two different forms (monohydrochloride or sulfate). O...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

Safety and efficacy of Cinergy® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B‐50508, B. amyloliquefaciens NRRL B‐50509 and Bacillus subtilis NRRL B‐50510) as a feed additive for pigs for fattening and minor porcine species

Safety and efficacy of Cinergy® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B‐50508, B. amyloliquefaciens NRRL B‐50509 and Bacillus subtilis NRRL B‐50510) as a feed additive for pigs for fattening and minor porcine species

Published on: Wed, 20 Mar 2019 The additive contains viable spores of two strains of Bacillus amyloliquefaciens and a single strain of Bacillus subtilis and is intended to be used with pigs for fattening and minor porcine species at a minimum inclusion level of 1.5 × 108 colony forming units (CFU)/kg complete feedingstuffs. The two bacterial species are considered suitable for the qualified presumption of safety (QPS) approach to safety assessment, which requires the identity of the strains to be establ...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Pest categorisation of Phymatotrichopsis omnivora

Pest categorisation of Phymatotrichopsis omnivora

Published on: Tue, 12 Mar 2019 The Panel on Plant Health performed a pest categorisation of Phymatotrichopsis omnivora, the causal agent of Phymatotrichum root rot of more than 2,000 dicotyledonous plant species, for the EU. The pest is listed as Trechispora brinkmannii in Annex IAI of Directive 2000/29/EC. P. omnivora is a well‐defined fungal species and reliable methods exist for its detection and identification. It is present in south‐western USA, northern Mexico, Libya and Venezuela. The pest is not...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Pest survey card on Popillia japonica

Pest survey card on Popillia japonica

Published on: Wed, 06 Mar 2019 This pest survey card was prepared in the context of the mandate on plant pest surveillance (EFSA‐Q‐2017‐00831), upon request by the European Commission. The purpose of this document is to assist the Member States in planning annual survey activities of quarantine organisms using a statistically sound and risk‐based pest survey approach, in line with the current international standards. The data requirements for such activity include the pest distribution, its host range, ...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Safety and efficacy of Robenz® 66G (robenidine hydrochloride) for chickens for fattening and turkeys for fattening

Published on: Tue, 05 Mar 2019 Following a request from European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Robenz® 66G (robenidine hydrochloride (HCl)) when used as a feed additive for chickens for fattening and turkeys for fattening. The coccidiostat Robenz®66G is considered safe for chickens for fattening at the highest proposed level of 36 mg robenidine HCl/kg complete feed with a ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Safety and efficacy of Beltherm MP/ML (endo-1,4-betaxylanase) as a feed additive for piglets, pigs for fattening and other porcine species

Safety and efficacy of Beltherm MP/ML (endo-1,4-betaxylanase) as a feed additive for piglets, pigs for fattening and other porcine species

Published on: Mon, 04 Mar 2019 Beltherm MP/ML contains endo-1,4-beta-xylanase and it is to be used as a zootechnical additive for weaned piglets, pigs for fattening and minor porcine species for fattening. The safety and efficacy of the additive when used for poultry species have been evaluated previously by the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel). In that assessment, the safety for the consumers, environment and the users was assessed. The applicant has ...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Safety and efficacy of Beltherm MP/ML (endo‐1,4‐beta‐xylanase) as a feed additive for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding, turkeys for breeding purposes and minor poultry species

Safety and efficacy of Beltherm MP/ML (endo‐1,4‐beta‐xylanase) as a feed additive for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding, turkeys for breeding purposes and minor poultry species

Published on: Fri, 01 Mar 2019 Beltherm MP/ML contains endo‐1,4‐beta‐xylanase and is intended to be used as a zootechnical additive for poultry species. The safety and efficacy of the additive have been evaluated by the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) in 2017. In that assessment, the additive and the production strain, a genetically modified strain of Bacillus subtilis, were characterised in full. No viable cells of the production strain were detecte...

Europe - EFSA - European Food Safety Authority EFSA Journal

5-3-2019

Safety and efficacy of Calsporin® (Bacillus subtilis DSM 15544) for all poultry species

Safety and efficacy of Calsporin® (Bacillus subtilis DSM 15544) for all poultry species

Published on: Fri, 01 Mar 2019 The additive Calsporin® is a preparation of viable spores of Bacillus subtilis DSM 15544, at a minimum declared concentration of 1 × 1010 colony forming units (CFU)/g additive. The additive is authorised as a zootechnical additive (functional group: gut flora stabiliser) for use in chickens for fattening, weaned piglets, chickens reared for laying, turkeys, minor avian species and other ornamental and game birds, laying hens and ornamental fish, dogs, in sows and in suckli...

Europe - EFSA - European Food Safety Authority EFSA Journal

26-2-2019

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Published on: Mon, 25 Feb 2019 Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the product TYFER™ (ferric tyrosine chelate) as zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breeding. The additive is safe for chickens for fattening at the maximum expected level of 200 mg TYFER™/kg complete feed; this conclusion can be extended to chickens reared for laying/breedin...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-2-2019

Jurnista (hydromorphone hydrochloride) prolonged-release

Jurnista (hydromorphone hydrochloride) prolonged-release

Product defect correction - potentially damaged tablets

Therapeutic Goods Administration - Australia

1-2-2019

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Safety of concentrated l‐lysine (base), l‐lysine monohydrochloride and l‐lysine sulfate produced using different strains of Corynebacterium glutamicum for all animal species based on a dossier submitted by FEFANA asbl

Published on: Thu, 31 Jan 2019 The EFSA FEEDAP Panel previously (2016) could not conclude on the safety of certain concentrated liquid l‐lysine (base), l‐lysine monohydrochloride (HCl) and l‐lysine sulfate products manufactured using different strains of Corynebacterium glutamicum. New information on the safety of these products was provided by the applicant. The recipient strain C. glutamicum KCTC 12307BP qualifies for qualified presumption of safety (QPS) approach for safety assessment, the genetic mo...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-2-2019

Safety and efficacy of l‐lysine monohydrochloride and concentrated liquid l‐lysine (base) produced by fermentation using Corynebacterium glutamicum strain NRRL B‐50775 for all animal species based on a dossier submitted by ADM

Safety and efficacy of l‐lysine monohydrochloride and concentrated liquid l‐lysine (base) produced by fermentation using Corynebacterium glutamicum strain NRRL B‐50775 for all animal species based on a dossier submitted by ADM

Published on: Thu, 31 Jan 2019 The European Commission asked EFSA for an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of a l‐lysine monohydrochloride (HCl, minimum 98.5%) and of a concentrated liquid l‐lysine (base, minimum 50%) produced by a genetically modified strain of Corynebacterium glutamicum(NRRL B‐50775). They are intended to be used in feed or water for drinking for all animal species and categories. Neither the production strain C. gluta...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Safety and efficacy of B‐Act® (Bacillus licheniformis DSM 28710) as a feed additive for turkeys for fattening, turkeys reared for breeding and minor poultry species for fattening or raised for laying

Published on: Mon, 14 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of B‐Act® when used in feed for turkeys for fattening, reared for breeding and minor poultry species for fattening or raised for laying. B‐Act® is a preparation containing viable spores of a Bacillus licheniformis strain. This species is considered by EFSA to be suitable for the qua...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Voluntary Recall Notice of El Guapo Chile Habanero and Chile Pasilla-Ancho Pouches Due to Unlabeled Peanut Allergen

Voluntary Recall Notice of El Guapo Chile Habanero and Chile Pasilla-Ancho Pouches Due to Unlabeled Peanut Allergen

Mojave Foods Corporation is initiating a voluntary recall of El Guapo Chile Habanero and Chile Pasilla-Ancho pouches due to an unlabeled peanut allergen.

FDA - U.S. Food and Drug Administration

18-12-2018

Apo-Prednisone 5 mg Tablet (2018-12-18)

Apo-Prednisone 5 mg Tablet (2018-12-18)

Health Canada

11-12-2018

International Lubricants, Inc. recalls Kool-It Evaporator & Heater Foam Cleaner

International Lubricants, Inc. recalls Kool-It Evaporator & Heater Foam Cleaner

The recalled product does not have proper consumer chemical hazard labelling as required by the Consumer Chemicals and Containers Regulations, 2001 under the Canada Consumer Product Safety Act.

Health Canada

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

27-11-2018

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx 2 Objective 1: Compendium of Representative Processing Techniques investigated in regulatory studies for pesticides

Database of processing techniques and processing factors compatible with the EFSA food classification and description system FoodEx 2 Objective 1: Compendium of Representative Processing Techniques investigated in regulatory studies for pesticides

Published on: Mon, 26 Nov 2018 EFSA is conducting pan‐European dietary exposure and risk assessments related to actual levels of pesticide residues in food commodities. These assessments use the pesticide occurrence data generated under the official monitoring programs of Member States, the consumption data from EFSA's comprehensive food consumption database and pesticide‐specific information such as processing factors. Currently no harmonised list of processing factors is available within Europe and wo...

Europe - EFSA - European Food Safety Authority Publications

13-11-2018

Setting of import tolerances for teflubenzuron in grapefruits, mandarins and broccoli

Setting of import tolerances for teflubenzuron in grapefruits, mandarins and broccoli

Published on: Mon, 12 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant BASF Agro BV submitted a request to the competent national authority in the United Kingdom to set import tolerances for the active substance teflubenzuron in grapefruits and mandarins imported from Brazil and for broccoli imported from Paraguay. The data submitted were found to be sufficient to derive maximum residue level (MRL) proposals for grapefruits and broccoli. The MRL derived ...

Europe - EFSA - European Food Safety Authority Publications

18-3-2019

EU/3/16/1742 (Worphmed Srl)

EU/3/16/1742 (Worphmed Srl)

EU/3/16/1742 (Active substance: Acebutolol hydrochloride) - Transfer of orphan designation - Commission Decision (2019)2157 of Mon, 18 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004715

Europe -DG Health and Food Safety

18-3-2019


Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of primary myelofibrosis, 05/08/2011, Positive

Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of primary myelofibrosis, 05/08/2011, Positive

Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of primary myelofibrosis, 05/08/2011, Positive

Europe - EMA - European Medicines Agency

18-3-2019


Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of post-essential thrombocythaemia myelofibrosis, 05/08/2011, Positive

Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of post-essential thrombocythaemia myelofibrosis, 05/08/2011, Positive

Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of post-essential thrombocythaemia myelofibrosis, 05/08/2011, Positive

Europe - EMA - European Medicines Agency

18-3-2019


Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of post-polycythaemia vera myelofibrosis, 05/08/2011, Positive

Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of post-polycythaemia vera myelofibrosis, 05/08/2011, Positive

Orphan designation: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt, Treatment of post-polycythaemia vera myelofibrosis, 05/08/2011, Positive

Europe - EMA - European Medicines Agency

18-3-2019


Orphan designation: Acebutolol hydrochloride, Treatment of Smith-Magenis syndrome, 14/10/2016, Positive

Orphan designation: Acebutolol hydrochloride, Treatment of Smith-Magenis syndrome, 14/10/2016, Positive

Orphan designation: Acebutolol hydrochloride, Treatment of Smith-Magenis syndrome, 14/10/2016, Positive

Europe - EMA - European Medicines Agency

15-3-2019

EU/3/06/349 (Vectura Ireland Limited)

EU/3/06/349 (Vectura Ireland Limited)

EU/3/06/349 (Active substance: Apomorphine hydrochloride (inhalation use)) - Transfer of orphan designation - Commission Decision (2019)2115 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004495

Europe -DG Health and Food Safety

6-3-2019

Fortekor and associated names

Fortekor and associated names

Fortekor and associated names (Active substance: Benazepril hydrochloride) - Corrigendum - Commission Decision (2012)772 of Wed, 06 Mar 2019

Europe -DG Health and Food Safety

26-2-2019

EU/3/11/888 (DLRC Pharma Services Ltd)

EU/3/11/888 (DLRC Pharma Services Ltd)

EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2019)1623 of Tue, 26 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003766

Europe -DG Health and Food Safety

26-2-2019

EU/3/11/887 (DLRC Pharma Services Ltd)

EU/3/11/887 (DLRC Pharma Services Ltd)

EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2019)1622 of Tue, 26 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003764

Europe -DG Health and Food Safety

26-2-2019

EU/3/11/886 (DLRC Pharma Services Ltd)

EU/3/11/886 (DLRC Pharma Services Ltd)

EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2019)1621 of Tue, 26 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003767

Europe -DG Health and Food Safety

20-2-2019


Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806

Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806

Glibenclamide / metformin hydrochloride: List of nationally authorised medicinal products - PSUSA/00002002/201806

Europe - EMA - European Medicines Agency

20-2-2019


Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018

Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018

Lidocaine hydrochloride / phenylephrine hydrochloride / tropicamide: List of nationally authorised medicinal products - PSUSA/00010390/2018

Europe - EMA - European Medicines Agency

20-2-2019


Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired

Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired

Orphan designation: Histamine dihydrochloride, Treatment of acute myeloid leukaemia, 11/04/2005, Expired

Europe - EMA - European Medicines Agency

20-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0354/2018

Europe - EMA - European Medicines Agency

19-2-2019


Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride, Treatment of Kabuki syndrome, 19/11/2018, Positive

Europe - EMA - European Medicines Agency

19-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018

Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018

Opinion/decision on a Paediatric investigation plan (PIP): Phenylephrine hydrochloride,ketorolac trometamol (OMS302), decision type: , therapeutic area: , PIP number: P/0362/2018

Europe - EMA - European Medicines Agency

5-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018

Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018

Opinion/decision on a Paediatric investigation plan (PIP): Landiolol (hydrochloride), decision type: , therapeutic area: , PIP number: P/0273/2018

Europe - EMA - European Medicines Agency

5-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018

Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018

Opinion/decision on a Paediatric investigation plan (PIP): Eviplera,emtricitabine,Rilpivirine (hydrochloride),Tenofovir (disoproxil fumarate), decision type: , therapeutic area: , PIP number: P/0274/2018

Europe - EMA - European Medicines Agency

4-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018

Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018

Opinion/decision on a Paediatric investigation plan (PIP): Edurant,Rilpivirine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0322/2018

Europe - EMA - European Medicines Agency

1-2-2019


Summary of opinion: Doxolipad,doxorubicin hydrochloride,  31/01/2019,  Negative

Summary of opinion: Doxolipad,doxorubicin hydrochloride, 31/01/2019, Negative

Summary of opinion: Doxolipad,doxorubicin hydrochloride, 31/01/2019, Negative

Europe - EMA - European Medicines Agency

31-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ciprofloxacin (hydrochloride), decision type: , therapeutic area: , PIP number: P/0253/2018

Europe - EMA - European Medicines Agency

31-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018

Opinion/decision on a Paediatric investigation plan (PIP): Cariprazine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0301/2018

Europe - EMA - European Medicines Agency

29-1-2019


Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805

Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805

Chlorphenoxamine hydrochloride : List of nationally authorised medicinal products - PSUSA/00010361/201805

Europe - EMA - European Medicines Agency

28-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018

Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018

Opinion/decision on a Paediatric investigation plan (PIP): Sarizotan (hydrochloride), decision type: , therapeutic area: , PIP number: P/0287/2018

Europe - EMA - European Medicines Agency

28-1-2019

Clomicalm (Elanco GmbH)

Clomicalm (Elanco GmbH)

Clomicalm (Active substance: Clomipramine hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)720 of Mon, 28 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/000039/T/0030

Europe -DG Health and Food Safety

23-1-2019


Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Orphan designation: 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride-, Treatment of diffuse large B-cell lymphoma, 27/06/2016, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Orphan designation: Doxorubicin hydrochloride (in heat-sensitive liposomes), Treatment of hepatocellular carcinoma, 23/02/2011, Positive

Europe - EMA - European Medicines Agency

16-1-2019

EU/3/18/2125 (Isabelle Ramirez)

EU/3/18/2125 (Isabelle Ramirez)

EU/3/18/2125 (Active substance: Benserazide hydrochloride) - Orphan designation - Commission Decision (2019)221 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000001719

Europe -DG Health and Food Safety

16-1-2019

EU/3/10/833 (FGK Representative Service GmbH)

EU/3/10/833 (FGK Representative Service GmbH)

EU/3/10/833 (Active substance: Doxorubicin hydrochloride (in heat-sensitive liposomes)) - Transfer of orphan designation - Commission Decision (2019)237 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003113

Europe -DG Health and Food Safety

16-1-2019

EU/3/16/1672 (Celgene Europe B.V.)

EU/3/16/1672 (Celgene Europe B.V.)

EU/3/16/1672 (Active substance: 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride) - Transfer of orphan designation - Commission Decision (2019)236 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003283

Europe -DG Health and Food Safety

11-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Opinion/decision on a Paediatric investigation plan (PIP): Octenidine (dihydrochloride), decision type: , therapeutic area: , PIP number: P/0240/2018

Europe - EMA - European Medicines Agency

18-12-2018

APO-Valsartan (valsartan) tablets

APO-Valsartan (valsartan) tablets

Recall - potential contamination

Therapeutic Goods Administration - Australia

13-12-2018


Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Overview of comments received on 'Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance' (EMA/CHMP/800775/2017)

Europe - EMA - European Medicines Agency

13-12-2018


Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

11-12-2018


Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803

Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803

Epinephrine mepivacaine hydrochloride, mepivacaine norepinephrine, mepivacaine: List of nationally authorised medicinal products - PSUSA/00001979/201803

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0177/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018

Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018

Opinion/decision on a Paediatric investigation plan (PIP): Mexiletine (hydrochloride), decision type: , therapeutic area: , PIP number: P/0210/2018

Europe - EMA - European Medicines Agency

28-11-2018

Econor (Elanco GmbH)

Econor (Elanco GmbH)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8038 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/42/T/54

Europe -DG Health and Food Safety

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu

Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-gu

Opinion/decision on a Paediatric investigation plan (PIP): ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride, decision type: , therapeutic area: , PIP number: P/0134/2018

Europe - EMA - European Medicines Agency

28-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018

Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018

Opinion/decision on a Paediatric investigation plan (PIP): naloxone (hydrochloride), decision type: , therapeutic area: , PIP number: P/0146/2018

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018

Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018

Opinion/decision on a Paediatric investigation plan (PIP): (R)-2-amino-3-phenylpropylcarbamate hydrochloride (solriamfetol), decision type: , therapeutic area: , PIP number: P/0207/2018

Europe - EMA - European Medicines Agency

26-11-2018

Wakix (Bioprojet Pharma)

Wakix (Bioprojet Pharma)

Wakix (Active substance: Pitolisant hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7974 of Mon, 26 Nov 2018

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Takeda Pharma A/S)

EU/3/18/2082 (Active substance: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride) - Orphan designation - Commission Decision (2018)7791 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/040/18

Europe -DG Health and Food Safety

13-11-2018

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01

Europe -DG Health and Food Safety

13-11-2018

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01

Europe -DG Health and Food Safety